

# Kent Academic Repository

## Full text document (pdf)

### Citation for published version

Rowe, Ceri and Sitch, Alice J. and Barratt, Jonathan and Brettell, Elizabeth A. and Cockwell, Paul and Dalton, R. Neil and Deeks, Jon J. and Eaglestone, Gillian and Pellatt-Higgins, Tracy and Kalra, Philip A. and Khunti, Kamlesh and Loud, Fiona C. and Morris, Frances S. and Ottridge, Ryan S. and Stevens, Paul E. and Sharpe, Claire C. and Sutton, Andrew J. and Taal, Maarten

### DOI

<https://doi.org/10.1016/j.kint.2019.02.021>

### Link to record in KAR

<https://kar.kent.ac.uk/74554/>

### Document Version

Author's Accepted Manuscript

#### Copyright & reuse

Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder.

#### Versions of research

The version in the Kent Academic Repository may differ from the final published version.

Users are advised to check <http://kar.kent.ac.uk> for the status of the paper. **Users should always cite the published version of record.**

#### Enquiries

For any further enquiries regarding the licence status of this document, please contact:

[researchsupport@kent.ac.uk](mailto:researchsupport@kent.ac.uk)

If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at <http://kar.kent.ac.uk/contact.html>

**Biological variation of measured and estimated glomerular filtration rate (GFR) in patients with chronic kidney disease: the eGFR-C Study**

Ceri Rowe,<sup>1\*</sup> Alice J Sitch,<sup>2, 3\*</sup> Jonathan Barratt,<sup>4</sup> Elizabeth A Brettell,<sup>5</sup> Paul Cockwell,<sup>6</sup> R Neil Dalton,<sup>7</sup> Jon J Deeks,<sup>2, 3, 5</sup> Gillian Eaglestone,<sup>8</sup> Tracy Pellatt-Higgins,<sup>9</sup> Philip A Kalra,<sup>10</sup> Kamlesh Khunti,<sup>11</sup> Fiona C Loud,<sup>12</sup> Frances S Morris,<sup>8</sup> Ryan S Ottridge,<sup>5</sup> Paul E Stevens,<sup>8</sup> Claire C Sharpe,<sup>13</sup> Andrew J Sutton,<sup>14</sup> Maarten W Taal,<sup>15</sup> Edmund J Lamb,<sup>1\*\*</sup> on behalf of the eGFR-C study group.

\*joint first authors

\*\* corresponding author

<sup>1</sup>Clinical Biochemistry, East Kent Hospitals University NHS Foundation Trust, Canterbury, Kent, CT1 3NG, UK, <sup>2</sup>Test Evaluation Research Group, University of Birmingham, Birmingham B15 2TT, UK, <sup>3</sup>NIHR Birmingham Biomedical Research Centre, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, B15 2TT, UK <sup>4</sup>University Hospitals of Leicester, <sup>5</sup>Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT UK, <sup>6</sup>Renal Medicine, Queen Elizabeth Hospital Birmingham and Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT UK, <sup>7</sup>Evelina London Children's Hospital, London SE1 7EH, <sup>8</sup>Kent Kidney Care Centre, East Kent Hospitals University NHS Foundation Trust, Canterbury, Kent, CT1 3NG, UK, <sup>9</sup>Centre for Health Services Studies, University of Kent, Canterbury, CT2 7NF, UK, <sup>10</sup>Salford Royal NHS Foundation Trust, Salford, M6 8HD, UK <sup>11</sup>University of Leicester, <sup>12</sup>Kidney Care UK, 3 The Windmills, Turk Street, Alton, Hampshire, GU34 1EF, UK, <sup>13</sup>King's College London & King's College Hospital NHS Foundation Trust, London, SE5 9RJ, <sup>14</sup>Leeds Institute of Health Sciences, University of Leeds, Leeds, LS2 9JT, <sup>15</sup>Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3NE, UK.

**Address correspondence to:** Dr Edmund Lamb, Consultant Clinical Scientist, Clinical Biochemistry, East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Canterbury, Kent, UK, CT1 3NG. Telephone: 01227 864112, Facsimile: 01227 783077, E-mail: [elamb@nhs.net](mailto:elamb@nhs.net)

**Source of support:** This study was funded by the NIHR Health Technology Assessment Programme (HTA 11/103/01).

**Running header:** Biological variation of GFR

**Word count (including abstract excluding references):** 3957

**Word count of abstract:** 250

### **Significance statement of key findings**

In this prospective study we have simultaneously, under controlled conditions, established the biological and analytical variability of glomerular filtration rate (GFR) and estimates of GFR in patients with moderate chronic kidney disease. Biological variability of estimates of GFR using the Modification of Diet in Renal Disease (MDRD) Study and Chronic Kidney Disease Epidemiology (CKD-EPI) equations were similar to each other, but slightly lower than that of GFR measured using iohexol clearance. Consequently estimated GFR would need to decline by approximately 14% for that change to be considered significant with 95% certainty, compared to an approximately 18% decline in measured GFR for the same degree of certainty. The data presented can be used to assist an objective understanding of GFR changes in clinical practice. Estimates of GFR are at least as reliable as measured GFR for monitoring changes over time but measured GFR should continue to be regarded as the preferred method when an accurate assessment of GFR is required.

## Abstract

When assessing changes in glomerular filtration rate (GFR) it is important to differentiate pathological change from intrinsic biological and analytical variation. GFR is measured using complex reference methods (e.g. iohexol clearance). In clinical practice measurement of creatinine and cystatin C is used in equations (e.g. Modification of Diet in Renal Disease [MDRD] or Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) to provide estimated GFR. We studied biological variability of measured and estimated GFR in twenty nephrology outpatients (10 male, 10 female; median age 71, range 50-80 years) with moderate CKD (GFR 30-59 mL/min/1.73 m<sup>2</sup>). Patients underwent weekly GFR measurement by iohexol clearance over four consecutive weeks. Simultaneously GFR was estimated using the MDRD, CKD-EPI<sub>creatinine</sub>, CKD-EPI<sub>cystatinC</sub> and CKD-EPI<sub>creatinine+cystatinC</sub> equations. Within-subject biological variation (CV<sub>i</sub>) expressed as a percentage [95% CI] for the MDRD (5.0% [4.3-6.1]), CKD-EPI<sub>creatinine</sub> (5.3% [4.5-6.4]), CKD-EPI<sub>cystatinC</sub> (5.3% [4.5-6.5]), and CKD-EPI<sub>creatinine+cystatinC</sub> (5.0% [4.3-6.2]) equations were broadly equivalent. CV<sub>i</sub> values for MDRD and CKD-EPI<sub>creatinine+cystatinC</sub> were lower (p=0.027 and p=0.022 respectively) than that of measured GFR (6.7% [5.6-8.2]). Reference change values (RCV), the point at which a true change in a biomarker in an individual can be inferred to have occurred with 95% probability were calculated: using the MDRD equation, positive and negative RCVs were 15.1% and 13.1% respectively. If an individual's baseline MDRD estimated GFR (mL/min/1.73 m<sup>2</sup>) was 59, significant increases or decreases would be to values >68 or <51 respectively. Within-subject variability of estimated GFR is lower than measured GFR. RCVs can be used to understand GFR changes in clinical practice.

**Keywords:** biological variation, creatinine, cystatin C, glomerular filtration rate, iohexol, kidney disease, MDRD, CKD-EPI

## Introduction

Chronic kidney disease (CKD) is prevalent in the general population<sup>1-4</sup> and is commonly identified using estimation of glomerular filtration rate (GFR). The aim of disease detection is to make decisions on therapeutic interventions, and to identify and manage those most likely to progress to kidney failure and/or those at high risk of morbidity and mortality. The ability of tests to identify which individuals with CKD are at high risk of progressive or fatal disease is a crucial issue. However, what constitutes progressive kidney disease has been variably defined. Furthermore, a significant problem has been the ability of GFR measurements and estimations to identify progression of kidney disease against background age-related change in GFR and the biological and measurement variability of both reference and estimated GFR.<sup>5</sup>

Ideally, for accuracy GFR would be measured using either inulin clearance or one of several surrogate 'reference methods' in specialist clinical use (e.g. plasma clearance of iothalamate, iohexol or <sup>51</sup>Cr ethylenediaminetetraacetic acid). However, these techniques are somewhat complex and time-consuming. Pragmatic estimates of GFR, based on serum creatinine or cystatin C measurement, or both, are widely used. As with any physiological measurement, GFR, whether measured or estimated, has an intrinsic within-subject biological variability (CV<sub>i</sub>). Knowledge of this variability is critical to appreciation of disease-related change. Using a variety of reference markers, earlier studies have reported within-subject coefficients of variation (CV%) for the biological variation of GFR ranging between 5.5% and 12.1%.<sup>6-12</sup> Whilst forming a useful basis for comparison, many of these previous estimates did not follow an appropriate construct for a biological variation study and do not permit comparison of measured and estimated GFR.<sup>13</sup>

An understanding of biological variation of disease markers is essential to the interpretation of changes in response to disease events. Critical evaluation of the

significance of changes in results obtained on analysis of serial specimens can be performed only by consideration of  $CV_I$  and analytical ( $CV_A$ ) variation.<sup>14</sup> These data enable the derivation of the reference change value (RCV), the point at which a true change in a biomarker in an individual can be inferred to have occurred with a stated degree of probability: typically 95% probability is chosen as this is conventionally regarded as significant.<sup>14,15</sup>

The aim of the present study is to define under standardised conditions the normal biological variability of measured GFR and hence derive mathematically the RCV. A subsidiary question is whether the  $CV_I$  and RCV are the same if estimated instead of measured GFR is used.

## **Results**

Characteristics of the study subjects are shown in Table 1. Medications were held constant during the four weeks of the study, except that two patients received a one week course of amoxicillin (500 mg tds) due to chest infection.

All 20 patients attended all four iohexol clearance procedures excepting one patient who missed one appointment. Results from five iohexol clearances (five separate patients) were excluded before analysis, as the dose given was not fully administered or it was given subcutaneously. Application of Cochran and Reed's tests led to the exclusion of between one and three duplicate measurements for measured or estimated GFR and to the exclusion of one outlying within-subject measurement for iohexol clearance (Supplementary Table S1). Overall, no patient was completely excluded and all calculations of biological variation for measured and estimated GFRs were based on a minimum of three weeks data in all individuals.

Estimates of components of biological variation are given in Table 2. The geometric exact  $CV_I$  value [95% CI] for measured GFR was 6.7% [5.6-8.2].  $CV_I$  values for the estimated GFR equations were broadly equivalent: MDRD 5.0% [4.3-6.1], CKD-EPI<sub>creatinine</sub> 5.3% [4.5-6.4], CKD-EPI<sub>cystatinC</sub> 5.3% [4.5-6.5], and CKD-EPI<sub>creatinine+cystatinC</sub> 5.0% [4.3-6.2] to each other. Modelling to investigate differences showed the  $CV_I$  for MDRD and CKD-EPI<sub>creatinine+cystatinC</sub> estimated GFRs to be significantly (at 5% level) lower than for measured GFR (difference -1.8%,  $p=0.027$  and difference -1.8%,  $p=0.022$  respectively, see Supplementary Table S2). Using the MDRD equation, positive and negative RCVs were 15.1% and 13.1% respectively. For example, if baseline MDRD GFR (mL/min/1.73 m<sup>2</sup>) in an individual is 59, significant increases or decreases would be to values >68 or <51 respectively.

Sensitivity analyses were carried out without outlier detection and deletion. Data were similar to those obtained following outlier removal, with analyses after outlier removal estimating slightly reduced CVs (Supplementary Table S3).

Modelling to identify any trends over time resulted in non-significant slopes (coef=-0.005; 95% CI (-0.020, 0.009);  $p=0.488$ ), thus providing no evidence of a change in disease state (kidney function) over the duration of the study.

## Discussion

To our knowledge, this is the first study to simultaneously establish the biological variation of measured and estimated GFR in patients with CKD. Following a recommended study design,<sup>13</sup> in a prospective study we observed the within-subject biological variation of measured GFR to be 6.7%, with similar, although in some cases significantly lower, biological variation of estimated GFR (5.0%, 5.3%, 5.3% and 5.0% for the MDRD, CKD-EPI<sub>creatinine</sub>, CKD-EPI<sub>cystatinC</sub> and CKD-EPI<sub>creatinine+cystatinC</sub> equations respectively). Taking

analytical and within-subject biological variability into account produced RCVs (% positive/negative) of 21.5/-17.7 (measured GFR), 15.1/-13.1 (MDRD), 15.9/-13.7 (CKD-EPI<sub>creatinine</sub>), 15.9/-13.8 (CKD-EPI<sub>cystatinC</sub>) and 15.1/-13.1 (CKD-EPI<sub>creatinine+cystatinC</sub>).

Although there have been several previous studies of the biological variation of GFR, few have followed the rigour of design required of a biological variation study.<sup>13,14</sup>

Nevertheless, several of these earlier studies report biological variability of measured GFR of a similar magnitude to that observed here, despite a variety of techniques and study designs; 4.5% (healthy individuals, plasma iohexol clearance),<sup>16</sup> 5.7% (CKD patients, plasma iohexol clearance),<sup>7</sup> 6.3% (CKD patients, renal <sup>125</sup>I-iothalamate clearance),<sup>8</sup> 5.5% (CKD patients with GFR >30 mL/min/1.73 m<sup>2</sup>, plasma <sup>51</sup>Cr-ethylenediaminetetraacetic acid [EDTA] clearance),<sup>6</sup> with some authors reporting higher estimates; 9.8% (CKD patients, plasma <sup>51</sup>Cr-EDTA clearance)<sup>10</sup> and 8.0% (CKD patients, <sup>99</sup>mTc-DTPA clearance).<sup>9</sup> Some of the differences observed may reflect the underlying level of kidney function in the groups studied: both Levey et al<sup>8</sup> and Brochner-Mortensen et al<sup>6</sup> report higher variation estimates in individuals with GFR<30 mL/min/1.73 m<sup>2</sup>. Other factors including length of time between repeat procedures (10 months) and total study duration (12 years),<sup>10</sup> inattention to hydration status, fasting and exercise before and during the test<sup>9</sup> may also have increased the variability reported in some studies.

When considering any change in a patient's results, healthcare practitioners need to be able to distinguish true change ('signal') from the 'noise' of variability. In clinical practice, biological variation is best considered in terms of the RCV, which takes both biological and analytical variation of measured GFR into account: the positive and negative RCVs of measured GFR were 21.5% and -17.7% respectively. Definitions of progressive kidney disease vary but it is important to consider whether, in the clinical context, the variability of measured GFR allows for detection of progressive kidney disease over a useful time frame. Reported 'normal' mean age-related decline in GFR of 1 mL/min/1.73 m<sup>2</sup>/year,<sup>17</sup> or



reported rates of decline of 3.6 mL/min/1.73 m<sup>2</sup>/year and 2.8 mL/min/1.73 m<sup>2</sup>/year respectively in male and female community dwelling older adults with diabetes and moderate CKD<sup>18</sup> could not be detected in individuals by annual GFR measurement. It is possible that reported annual mean GFR declines of 7.0 mL/min/1.73 m<sup>2</sup>/year amongst proteinuric (greater than 1 g/24 h) patients could be detected by annual monitoring of individual patient's GFR.<sup>19</sup> Importantly, based on the data presented here, monitoring of GFR will permit detection of progressive kidney disease as defined by recent guideline recommendations from Kidney Disease Improving Global Outcomes (KDIGO) and the National Institute for Health and Care Excellence (NICE). Both guidelines define a certain drop in GFR as an increase in disease category (e.g. G3a [GFR 45-59 mL/min/1.73 m<sup>2</sup>] to G3b [GFR 30-44 mL/min/1.73 m<sup>2</sup>]) accompanied by a fall in GFR of greater than or equal to 25% between two serial results. Alternatively, they define a significant change as a decrease in GFR of 15 mL/min/1.73 m<sup>2</sup> or more per year.<sup>5,20</sup> For example: if baseline measured GFR in an individual is 59 mL/min/1.73 m<sup>2</sup>, significant increases or decreases would be to values >72 or <48 mL/min/1.73 m<sup>2</sup>. Given the lower CV<sub>I</sub> and CV<sub>A</sub> of estimated GFR, slightly lower RCVs may be applied when monitoring patients using GFR estimating equations (e.g. if an individual's baseline MDRD estimated GFR was 59, significant increases or decreases would be to values >68 or <51 mL/min/1.73 m<sup>2</sup> respectively). However, it must be remembered that our biological variation estimates are obtained under idealised conditions, with optimisation of preanalytical variables and precise laboratory methods. In an uncontrolled operational clinical environment, it is likely that biological and analytical variation, and hence RCVs, would increase.

The within-subject biological variation of serum creatinine we have observed (4.4%) is in broad agreement with values reported in other studies in both healthy (4.1% to 7.6%,<sup>16,21-28</sup>) and diseased (5.7% to 9.9%<sup>23,29-31</sup>) cohorts. Enzymatic creatinine methods are less prone to interference than Jaffe methods and the use of an enzymatic assay in the present study improves confidence in the estimate of biological variation we have

reported. Whilst calculation of  $CV_I$  excludes any contribution due to  $CV_A$ , it cannot account for biological variability of non-creatinine chromogens (e.g. bilirubin, glucose, ketones, protein, and certain drugs) that are known to interfere in Jaffe methods of creatinine measurement. Similarly, our reported within-subject biological variation of cystatin C (4.0%) is similar to most (3.1%,<sup>32</sup> 4.1%,<sup>25</sup> 4.5%<sup>16,27</sup> and 4.8%<sup>29</sup>) but not all (6.8%,<sup>28</sup> 8.6%<sup>23</sup> and 13.3%<sup>24</sup>) previous estimates. As for measured GFR, differences in study design and data analysis may account for differences in reported estimates of variation: for example, most of these studies did not report their approach to outlier detection; the time interval between repeat sampling was prolonged in some studies.<sup>28</sup>

Depending on the equation used, estimated GFR is based on the concentration of creatinine, cystatin C or both. Therefore estimated GFR will have a similar  $CV_I$  to creatinine or cystatin C, mathematically inflated by the power function in the respective equation. The point estimates for  $CV_I$  of the four studied equations lie between 5.0% and 5.3% and have overlapping confidence intervals.

It is uncertain why the  $CV_I$  of estimated GFR should be lower than that of measured GFR. Probably the complexity of the iohexol clearance procedure, involving multiple measurements and blood samplings, contributes to a higher  $CV_I$  for measured than estimated GFR. However, it is also possible that the variability of estimated GFR is somewhat attenuated compared to physiological fluctuations in measured GFR, as noted, in an extreme example, following renal insult in acute kidney injury where there is a delay between the fall in GFR and the consequent rise in blood creatinine concentration.

These data have implications for the use of measured versus estimated GFR in clinical practice and research. Within-subject biological variation of measured GFR was similar to that of estimated GFR, implying no disadvantage to the use of simple estimates of GFR when monitoring patients over time. The main priority for monitoring GFR is to detect

change and for this purpose estimated GFR is at least as reliable as measured GFR. This is important because measurement of GFR is time consuming and more costly than estimated GFR. However, this should not be interpreted as an indication that estimated GFR should replace measured GFR when an accurate assessment of GFR is required. Reference techniques are considered more accurate than estimated GFR primarily because they are not influenced by the non-GFR determinants of endogenous filtration markers. Reference GFR measurements will remain important as the benchmark in clinical research studies and to inform clinical situations in which more accurate knowledge of GFR is important. These situations include certain chemotherapies (e.g. carboplatin); the use of any drug that is nephrotoxic or renally-excreted and has a narrow therapeutic margin; the assessment of potential living related kidney donors; the assessment of GFR in patients with muscle-wasting disorders, including spina bifida and paraplegia; those undergoing nephrectomy or partial nephrectomy; and in certain paediatric renal patients.

The strengths of this study include the use of an enzymatic creatinine assay and a three-point iohexol clearance procedure with the final sample being taken at 4 h postinjection, which is considered suitable for patients with  $\text{GFR} > 30 \text{ mL/min/1.73 m}^2$ .<sup>33</sup> The study was adequately powered<sup>34</sup> and followed a strict design to minimise preanalytical variation and investigator bias (Supplementary Table S4).<sup>13</sup> Outliers were excluded using a formal exclusion protocol: sensitivity testing was undertaken using excluded data to confirm that presented results were representative. Estimation of components of variation was derived using a nested ANOVA approach, which takes into account analytical variation for estimation of within-subject biological variation. The studied patient group represents a major population in which monitoring of kidney function to detect worsening disease is regularly undertaken and which is mandated in international guidance.<sup>5,20</sup> Prescribed medication was unaltered during the study, with the exception of two patients who received a course of amoxicillin. No patients showed significant trends in GFR during the

study period, confirming that the variation we have reported is physiological and not pathological in nature.

Our study has some limitations. The cohort studied was recruited from a single centre and was exclusively Caucasian: biological variability estimates may not be transferable to other ethnic groups. Although the study was adequately powered to answer the primary question, we were unable to investigate whether variability is higher at differing levels of GFR or albuminuria. Although previous studies have observed statistically significant differences in  $CV_I$  when individuals are stratified for level of GFR/albuminuria<sup>29</sup> such effects are unlikely to be of practical importance.<sup>25</sup> Our measured GFR data was based on a plasma iohexol clearance procedure. Whilst constant infusion urinary inulin clearance would be considered the reference measure of GFR, single-bolus plasma clearance of iohexol demonstrates good agreement with this technique and is widely used in clinical practice.<sup>35</sup> In terms of  $CV_I$ , plasma clearance techniques are likely to produce lower values than urinary clearance techniques due to problems of inaccurate urine collection. We have chosen to calculate RCVs representing 95% probability, as is conventional. However, if a lower probability was considered clinically acceptable, then the RCV would be smaller.<sup>22</sup>

In clinical practice, in the setting of CKD identification of deterioration of kidney function tends to be based not upon two consecutive results but on multiple observations obtained over a period of time. Traditional RCV calculations only allow comparison between two consecutive measurements. When multiple measurements are available then use of RCV values as described herein will be susceptible to the effect of repeated testing, where the probability of a false-positive result increases with the number of results available.

Because of this, in general terms RCV values increase with the number of observations available (i.e. a larger change is required compared to the baseline value to be deemed significant). Adjustments to the RCV calculation dependent on the number of results have been published but are relatively complex.<sup>36,37</sup> Because of this, and also because our

patients were being studied within relatively controlled conditions as discussed above, the RCV values we have reported should be considered minimum values: in clinical practice, for the same certainty of change, larger RCVs may be required.

In conclusion we describe the biological variability of measured and estimated GFR in a carefully designed study. The data generated have implications for monitoring of patients with CKD and clinical ability to detect CKD progression, both in clinical practice and in clinical trials, whether using measured or estimated GFR. Within-subject biological variation of measured GFR is similar to that of estimated GFR and, in terms of variability, suggests no real advantage to the use of measured GFR when monitoring patients over time. Nevertheless, measurement of GFR should continue to be regarded as the optimal approach when an accurate assessment of GFR is required. Most importantly, the information presented provides an evidence-base allowing clinicians to have meaningful discussions with their patients about the implications of changes in their GFR results.

## **Methods**

Chronic kidney disease patients (n=20) with MDRD estimated GFR between 30 and 59 mL/min/1.73 m<sup>2</sup> sustained over at least 90 days were recruited at the Kent Kidney Care Centre, UK between August 2014 and July 2015.<sup>38</sup> Patients with diabetes and proteinuria (ACR >30 mg/mmol) were included in the study. Patients who had a history of reaction to iodinated contrast media, who were pregnant, who had an episode of acute kidney injury within the last six months, amputees and those with an inability to consent due to cognitive impairment were excluded from the study. Patients provided written informed consent and the study had ethical approval (South-East Coast-Surrey Research Ethics Committee of the National Research Ethics Service reference number 13/LO/1349). The study conforms to the internationally agreed checklist for the reporting of studies of biological variation (Supplementary Table S4).<sup>13</sup>

The sample size was based on the precision of  $CV_1$ , which was estimated to be 10%. With twenty participants recruited, tested on four occasions and assayed in duplicate and assuming data are log-normally distributed, an approximate 95% confidence interval (CI) for  $CV_1$  has limits  $\pm 2\%$  (absolute).

### Measurement and estimation of GFR

Patients underwent four iohexol reference measures of GFR in four successive weeks, with standardisation for time of day and day of week. Participants were asked to follow a permitted food list from 22:00 the night before the procedure, being permitted a light breakfast with no high protein foods on the morning of the procedure. Demographic data, comorbidity information and prescription histories were recorded and blood pressure, weight and height documented. Blood samples were taken immediately prior to iohexol injection for serum creatinine and cystatin C measurement. Blood samples were collected using standard venepuncture procedures, including the use of a tourniquet, into gel-separator (for serum cystatin and creatinine) and lithium heparin (for plasma iohexol) containing Vacuette™ tubes (Greiner Bio-One International) following manufacturer's recommended order of draw. Plasma/serum was separated by centrifugation within 4 h of venepuncture and sample aliquots were stored at  $-80^{\circ}\text{C}$  pending analysis. All analyses were undertaken within 9 months of venepuncture at a central laboratory.

A 5 mL bolus of Omnipaque 240 (518 g/L iohexol corresponding to 240 g/L iodine, GE Healthcare [www.gelifesciences.com](http://www.gelifesciences.com)) followed by 10 mL physiological saline was injected into the antecubital vein. A blood sample was taken at 5 minutes from the opposite arm to confirm that the iohexol had been administered intravenously. Further blood samples were collected at 120, 180 and 240 minutes after injection. Exact times of blood draws in relation to injection time were recorded. During the procedure individuals were allowed

free access to fluids (no carbonated drinks), but asked to refrain from protein intake and excessive exercise.

Detailed laboratory methods are available in the supplementary file. Briefly, iohexol was measured using electrospray isotope dilution tandem mass spectrometry. Iohexol concentrations were log transformed (natural log) and plotted as a function of time. GFR was calculated from the slope-intercept method using a single compartment model,  $GFR \text{ (mL/min)} = 0.693 \times \text{iohexol volume of distribution (L)} \times 1000/\text{half-life of iohexol (min)}$ . GFR was adjusted for body surface area (BSA)<sup>39</sup> and then corrected for the fast exponential.<sup>40</sup>

Serum creatinine was measured using an enzymatic assay standardised to the reference material, NIST SRM 967 and 914. Between-day imprecision (coefficient of variation, %) was 0.8%, 0.3% and 0.4% at concentrations of 75, 176 and 760  $\mu\text{mol/L}$  respectively. Cystatin C was measured by a turbidimetric immunoassay calibrated against the international certified reference material ERM-DA471/IFCC for cystatin C.<sup>41</sup> GFR was estimated using the simplified isotope dilution mass-spectrometric (ID-MS) traceable version of the MDRD equation<sup>42</sup> and the three CKD-EPI equations:  $\text{CKD-EPI}_{\text{creatinine}}$ ,  $\text{CKD-EPI}_{\text{cystatinC}}$  and  $\text{CKD-EPI}_{\text{creatinine-cystatinC}}$ .<sup>43,44</sup>

### Statistical analysis

Data were log-transformed and normality tests were performed using the Shapiro-Wilk test. Outliers between duplicate measurements and of within-subject variance were excluded using Cochran's test and outliers amongst mean values of subjects were excluded using Reed's test as advocated by Fraser and Harris.<sup>14</sup> Sensitivity analyses were also performed without exclusion of identified outliers. Log transformation was used to simplify calculation and because it improved the normality of the data as assessed by

an increase in Shapiro–Wilk W statistic and visual examination of the distributions (Supplementary Figure S1 and Table S5).

Terminology used was as proposed by Simundic et al.<sup>45</sup> Analytical ( $CV_A$ ),  $CV_I$  and between-subject ( $CV_G$ ) components of variation were calculated using standard approaches<sup>14</sup> of linear random effects modelling with restricted maximum likelihood estimation (allowing for the clustering of observations within time points and repeated observations per patient) (Stata version 15). Exact geometric CVs [ $\sqrt{\exp(S^2) - 1} \times 100$ ,<sup>46,47</sup>] were calculated. Confidence intervals for SDs and CVs were estimated as described by Burdick and Graybill.<sup>48</sup> Differences in measures of CV, comparing the estimated GFR measures to measured GFR were investigated using multilevel models accounting for the clustering of test observations within individuals, using unstructured covariance matrices, in addition to the clustering of test results (multiple results per person, observation points and assessments). The RCV for a change in GFR between two results with 95% probability was calculated using the approach for log-normal data giving a negative and positive limit.<sup>49</sup> The number of specimens (n) required to produce a precise estimate of the homeostatic set-point with 95% confidence within  $\pm 10\%$  was calculated as:

$$n = [1.96 \cdot (CV_I^2 + CV_A^2)^{1/2} / 10]^2$$

For each biomarker the index of individuality (II) was calculated as:

$$II = (CV_I^2 + CV_A^2)^{1/2} / CV_G$$

To confirm kidney function was stable across the study period, the iohexol GFR measures were modelled to identify trend with time using a multilevel linear regression model



(allowing for clustering of assessments within time points and observations within individuals).

### **Abbreviations:**

ACR: Albumin to creatinine ratio; ANOVA; analysis of variance; BSA: body surface area; CI: confidence interval; CKD: chronic kidney disease; CKD-EPI: Chronic Kidney Disease-Epidemiology Consortium; CV: coefficient of variation;  $CV_A$ : analytical coefficient of variation;  $CV_G$ : between-subject biological variation;  $CV_I$ : within-subject biological variation;  $CV_T$ : total coefficient of variation; EDTA, ethylenediaminetetraacetic acid; eGFR: estimated glomerular filtration rate; GFR: glomerular filtration rate; ID-MS: isotope dilution mass spectrometry; KDIGO: Kidney Disease Improving Global Outcomes; MDRD: Modification of Diet in Renal Disease; mGFR: measured glomerular filtration rate; NICE: National Institute for Health and Care Excellence; RCV: reference change value

### **Disclosure:**

All authors declare no competing interests.

### **Acknowledgements:**

This study was funded by the NIHR Health Technology Assessment Programme (HTA 11/103/01). The NIHR Research Design Service South-East contributed to the development of this study including comments from the patient and public involvement unit. AS and JJD are supported by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The NIHR CRN portfolio study number is 15268. The study is registered as ISRCTN42955626 and on clinical trials.gov as NCT02433002. Further information may be found on the study website

<http://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/renal/egfr-c/index.aspx>

(accessed 23rd July 2018).

**Author's contributions:**

All authors contributed to the intellectual content and have met the following requirements:

(a) significant contributions to the concept, (b) drafting or revising the article for intellectual content and (c) reading and approval of the final manuscript. Specific contribution: CR and ASi carried out the statistical analyses and reported the results.

**Department of Health Disclaimer:**

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

**Supplementary material:**

Supplementary methods

Figure S1. Effect of log transformations on distributions

Table S1. Identification of outliers by Cochran's and Reed's criterion.

Table S2. Differences between measures using each GFR estimate compared with measured GFR (calculated as eGFR-mGFR).

Table S3. Summary of components of variation for creatinine and cystatin C and measured and estimated glomerular filtration rate (GFR) *without outlier detection and removal*

Table S4. Critical appraisal checklist for studies of biological variation

Table S5. Shapiro-Wilk normality test p-values before and after log transformation.

Supplementary information is available at *Kidney International's* website

## References:

1. Carter JL, Stevens PE, Irving JE, Lamb EJ. Estimating glomerular filtration rate: comparison of the CKD-EPI and MDRD equations in a large UK cohort with particular emphasis on the effect of age. *QJM* 2011; **104**(10): 839-47.
2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 2003; **41**(1): 1-12.
3. Stevens PE, O'Donoghue DJ, de Lusignan S, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. *Kidney Int* 2007; **72**(1): 92-9.
4. Roth M, Roderick P, Mindell J. Chapter 3: Kidney Disease and renal function in Health Survey for England 2009: NHS Information Centre; 2010 Available from: <http://www.ic.nhs.uk/statistics-and-data-collections/health-and-lifestyles-related-surveys/health-survey-for-england>.
5. National Institute for Health and Care Excellence. Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care. 2014: <http://www.nice.org.uk/nicemedia/live/13712/66658/.pdf>.
6. Brochner-Mortensen J, Rodbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. *Scand J Clin Lab Invest* 1976; **36**(1): 35-43.
7. Gaspari F, Perico N, Matalone M, et al. Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. *J Am Soc Nephrol* 1998; **9**(2): 310-3.
8. Levey AS, Greene T, Schluchter MD, et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. *J Am Soc Nephrol* 1993; **4**(5): 1159-71.
9. Wilkinson J, Fleming JS, Waller DG. Effect of food and activity on the reproducibility of isotopic GFR estimation. *Nucl Med Commun* 1990; **11**(10): 697-700.

10. Blake GM, Roe D, Lazarus CR. Long-term precision of glomerular filtration rate measurements using <sup>51</sup>Cr-EDTA plasma clearance. *Nucl Med Commun* 1997; **18**(8): 776-84.
11. Perrone RD, Steinman TI, Beck GJ, et al. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of <sup>125</sup>I-iothalamate, <sup>169</sup>Yb-DTPA, <sup>99m</sup>Tc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. *Am J Kidney Dis* 1990; **16**(3): 224-35.
12. Kwong YT, Stevens LA, Selvin E, et al. Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. *Am J Kidney Dis* 2010; **56**(1): 39-49.
13. Bartlett WA, Braga F, Carobene A, et al. A checklist for critical appraisal of studies of biological variation. *Clin Chem Lab Med* 2015; **53**(6): 879-85.
14. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. *Crit Rev Clin Lab Sci* 1989; **27**(5): 409-37.
15. Fraser CG, Hyltoft Petersen P, Libeer JC, Ricos C. Proposals for setting generally applicable quality goals solely based on biology. *Ann Clin Biochem* 1997; **34**: 8-12.
16. Delanaye P, Cavalier E, Depas G, Chapelle JP, Krzesinski JM. New data on the intraindividual variation of cystatin C. *Nephron Clin Pract* 2008; **108**(4): c246-8.
17. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. *J Am Geriatr Soc* 1985; **33**(4): 278-85.
18. Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. *Kidney Int* 2006; **69**(12): 2155-61.
19. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. *J Am Soc Nephrol* 2001; **12**(12): 2832-7.
20. Kidney Disease Improving Global Outcomes. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International* 2013; **3**: (Suppl.): 1-150.

21. Gowans EM, Fraser CG. Biological variation of serum and urine creatinine and creatinine clearance: ramifications for interpretation of results and patient care. *Ann Clin Biochem* 1988; **25**: 259-63.
22. Carobene A, Marino I, Coskun A, et al. The EuBIVAS Project: within- and between-subject biological variation data for serum creatinine using enzymatic and alkaline picrate methods and implications for monitoring. *Clin Chem* 2017; **63**(9): 1527-36.
23. Reinhard M, Erlandsen EJ, Randers E. Biological variation of cystatin C and creatinine. *Scand J Clin Lab Invest* 2009; **69**(8): 831-6.
24. Keevil BG, Kilpatrick ES, Nichols SP, Maylor PW. Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. *Clin Chem* 1998; **44**(7): 1535-9.
25. Waikar SS, Rebholz CM, Zheng Z, et al. Biological Variability of Estimated GFR and Albuminuria in CKD. *Am J Kidney Dis* 2018; **72**: 538-546.
26. Toffaletti JG, McDonnell EH. Variation of serum creatinine, cystatin C, and creatinine clearance tests in persons with normal renal function. *Clin Chim Acta* 2008; **395**(1-2): 115-9.
27. Bandaranayake N, Ankrah-Tetteh T, Wijeratne S, Swaminathan R. Intra-individual variation in creatinine and cystatin C. *Clin Chem Lab Med* 2007; **45**(9): 1237-9.
28. Selvin E, Juraschek SP, Eckfeldt J, Levey AS, Inker LA, Coresh J. Within-person variability in kidney measures. *Am J Kidney Dis* 2013; **61**(5): 716-22.
29. Carter JL, Parker CT, Stevens PE, et al. Biological variation of plasma and urinary markers of acute kidney injury in patients with chronic kidney disease. *Clin Chem* 2016; **62**(6): 876-83.
30. Podracka L, Feber J, Lepage N, Filler G. Intra-individual variation of cystatin C and creatinine in pediatric solid organ transplant recipients. *Pediatr Transplant* 2005; **9**(1): 28-32.
31. Tan GD, Lewis AV, James TJ, Altmann P, Taylor RP, Levy JC. Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes:

reproducibility and accuracy compared with standard measures and iohexol clearance.

*Diabetes Care* 2002; **25**(11): 2004-9.

32. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. *Nephrol Dial Transplant* 2003; **18**(10): 2024-31.

33. Fleming JS, Nunan TO. The new BNMS guidelines for measurement of glomerular filtration rate. *Nucl Med Commun* 2004; **25**(8): 755-7.

34. Roraas T, Petersen PH, Sandberg S. Confidence intervals and power calculations for within-person biological variation: effect of analytical imprecision, number of replicates, number of samples, and number of individuals. *Clin Chem* 2012; **58**(9): 1306-13.

35. Soveri I, Berg UB, Bjork J, et al. Measuring GFR: a systematic review. *Am J Kidney Dis* 2014; **64**(3): 411-24.

36. Lund F, Petersen PH, Fraser CG, Soletormos G. Calculation of limits for significant bidirectional changes in two or more serial results of a biomarker based on a computer simulation model. *Ann Clin Biochem* 2015; **52**(Pt 4): 434-40.

37. Lund F, Petersen PH, Fraser CG, Soletormos G. Calculation of limits for significant unidirectional changes in two or more serial results of a biomarker based on a computer simulation model. *Ann Clin Biochem* 2015; **52**(Pt 2): 237-44.

38. Lamb EJ, Brettell EA, Cockwell P, et al. The eGFR-C study: accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease--prospective longitudinal study in a multiethnic population. *BMC Nephrol* 2014; **15**(1): 13.

39. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. *J Pediatr* 1978; **93**(1): 62-6.

40. Brochner-Mortensen J. A simple method for the determination of glomerular filtration rate. *Scand J Clin Lab Invest* 1972; **30**(3): 271-4.

41. Grubb A, Blirup-Jensen S, Lindstrom V, Schmidt C, Althaus H, Zegers I. First certified reference material for cystatin C in human serum ERM-DA471/IFCC. *Clin Chem Lab Med* 2010; **48**(11): 1619-21.
42. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann Intern Med* 2006; **145**(4): 247-54.
43. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; **150**(9): 604-12.
44. Inker L, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med* 2012; 367:20-9.
45. Simundic AM, Kackov S, Miler M, Fraser CG, Petersen PH. Terms and symbols used in studies on biological variation: the need for harmonization. *Clin Chem* 2015; **61**(2): 438-9.
46. Cole TJ. Sympercents: symmetric percentage differences on the 100 log(e) scale simplify the presentation of log transformed data. *Statistics in medicine* 2000; **19**(22): 3109-25.
47. Koopmans LH, Owen DB, Rosenblatt JI. Confidence intervals for the coefficient of variation for the normal and log normal distributions. *Biometrika* 1964; **51**(1-2): 25-32.
48. Burdick RK, Graybill FA. Confidence Intervals on Variance Components: Taylor & Francis; 1992.
49. Fokkema MR, Herrmann Z, Muskiet FA, Moecks J. Reference change values for brain natriuretic peptides revisited. *Clin Chem* 2006; **52**(8): 1602-3.

**Table 1. Characteristics of the study population.** Values for continuous data are shown as median (range). Anthropometric data is based on baseline measurements. Estimated and measured\* GFR, creatinine and cystatin C data are calculated using all values over the four weeks.

n	20
Age, y	71 (50-80)
M:F	10:10
Caucasian (n)	20
Height, cm	170.5 (154-194)
Weight, kg	79.5 (47.1-118.1)
Body surface area, m <sup>2</sup>	1.99 (1.42-2.47)
Body mass index, kg/m <sup>2</sup>	28.2 (19.6-40.9)
Medication record (n)	Thiazide diuretic (3), loop diuretic (3), potassium sparing diuretic (2), beta-blocker (7), calcium antagonist (4), ACE inhibitor (8), angiotensin 2 receptor blocker (6), alpha-blocker (1), isosorbide mononitrate (1), HMG CoA reductase inhibitor (13), allopurinol (4), antiplatelet drugs (7)
Comorbidity (n)	Type 2 diabetes mellitus (3), ischaemic heart disease (7), angina (1), heart failure (2)
Smoker – current/former (n)	1/10
Urine albumin concentration <3 mg/mmol (n)	9
Urine albumin concentration 3-30 mg/mmol (n)	7
Urine albumin concentration >30 mg/mmol (n)	4
Serum creatinine, µmol/L	124 (79-182)
Serum cystatin C, mg/L	1.67 (1.01-2.30)
Measured GFR, mL/min/1.73 m <sup>2</sup>	49.0 (30.8-71.6)*
MDRD, mL/min/1.73 m <sup>2</sup>	42.2 (31.5-61.4)



CKD-EPI <sub>creatinine</sub> , mL/min/1.73 m <sup>2</sup>	43.0 (30.8-62.8)
CKD-EPI <sub>cystatinC</sub> , mL/min/1.73 m <sup>2</sup>	36.8 (23.5-67.1)
CKD-EPI <sub>creatinine+cystatinC</sub> , mL/min/1.73 m <sup>2</sup>	38.2 (27.2-65.4)

---

Abbreviations: ACE, angiotensin converting enzyme; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; HMG, hydroxymethyl glutaryl; MDRD, Modification of Diet in Renal Disease

\*Excludes data from five failed iohexol procedures (five separate patients).

**Table 2. Summary of components of variation for creatinine and cystatin C and measured and estimated glomerular filtration rate (GFR)**

	Measured GFR	Creatinine	Cystatin C	Estimated GFR			
				MDRD	CKD-EPI <sub>creatinine</sub>	CKD-EPI <sub>CystatinC</sub>	CKD-EPI <sub>creatinine+CystatinC</sub>
Geometric exact							
CV <sub>A</sub> (%)	2.3 (1.9, 2.7)	0.7 (0.6, 0.8)	0.6 (0.5, 0.7)	0.8 (0.7, 0.9)	0.8 (0.7, 1.0)	0.7 (0.6, 0.9)	0.6 (0.5, 0.7)
CV <sub>I</sub> (%)	6.7 (5.6, 8.2)	4.4 (3.7, 5.3)	4.0 (3.4, 4.9)	5.0 (4.3, 6.1)	5.3 (4.5, 6.4)	5.3 (4.5, 6.5)	5.0 (4.3, 6.2)
CV <sub>G</sub> (%)	16.7 (12.5, 24.9)	20.0 (15.0, 29.6)	19.0 (14.4, 28.2)	17.8 (13.4, 26.0)	19.3 (15.5, 29.2)	25.2(18.9, 37.5)	20.2 (15.2, 30.0)
Positive RCV (%)	21.5	13.0	11.8	15.1	15.9	15.9	15.1
Negative RCV (%)	-17.7	-11.5	-10.6	-13.1	-13.7	-13.8	-13.1
Homeostatic set point	2	1	1	1	1	1	1
Index of Individuality	0.4	0.2	0.2	0.3	0.3	0.2	0.3

All CV values expressed as percentages. 95% confidence intervals were calculated using methods of Burdick and Graybill.<sup>48</sup>

Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CV<sub>A</sub>, analytical variation; CV<sub>G</sub>, between-subject variation; CV<sub>I</sub>, within-subject biological variation; MDRD, Modification of Diet in Renal Disease; RCV, reference change value

